Therascreen KRAS PCR Kit NOW clinically validated for both colon and lung cancers

Therascreen KRAS PCR Kit NOW clinically validated for both colon and lung cancers

Anatomy - Pathology / Molecular Diagnostics

February 04, 2015

This new kit now increases the clinical claims for KRAS from metastatic Colorectal Cancer (mCRC)  to include also FFPE samples from Non-Small Cell Lung Cancer (NSCLC).

This claim extension is based on results from Phase III trials on advanced NSCLC patients.   

This new kit strengthen QIAGEN PHC strategy and positioning of continuously bringing to the market clinically proven and clinically validated IVD products to help pathologists and clinicians to provide the best medicine for their patients.

Lung cancer is the leading cause of cancer death globally. It kills more people than breast, colorectal and prostate cancers combined. NSCLC accounts for 85 percent of all lung cancer cases, and around 246,000 and around 400,000 news cases were diagnosed in 2014 in the US and in EU respectively.
 
Key Biomarkers in Non-Small Cell Lung Cancer
Several biomarkers have been identified in NSCLC. KRAS mutations represent the most common molecular change in NSCLC and the presence of KRAS mutations has been shown to be associated with a poor prognosis in NSCLC. The KRAS gene is a driver mutation in about 25% to 30% of NSCLC cases. This is why there is highest interest to develop anti-KRAS drugs for NSCLC.

This new kit completes the current NSCLC QIAGEN product offerings, like therascreen EGFR RGQ PCR kit for detection of EGFR mutations to guide treatment decisions with EGFR Tyrosine Kinase Inhibitors and the upcoming CE-IVD therascreen ALK RT-PCR Kit detecting ALK rearrangement expressions for treatment with ALK-targeted inhibitors.

EGFR mutations and ALK rearrangements are today the only available targets for personalized therapies in NSCLC employing drugs such as gefitinib, afatinib or crizotinib. In parallel many trials are conducted for targeted therapies for KRAS mutant NSCLC patients. These drugs will hit the market in coming years.

Antibody products against PEG from Abcam!

Antibody products against PEG from Abcam!

Anatomy - Pathology / Molecular Diagnostics

Polyethylene glycol (PEG) is a synthetic polymer composed of repeating ethylene glycol (-CH2-CH2-O-) units. It has low toxicity, is strongly hydrophilic and has a large exclusion volume in aqueous solution. The covalent attachment of PEG (PEGylation) is commonly used to modify a variety of proteins and drugs. PEGylation can offer several benefits including decreased immunogenicity, increased bioavailability, and optimized pharmacokinetics5.

 

 

April 15, 2019 More +
Ochratoxin A in Spices

Ochratoxin A in Spices

Anatomy - Pathology / Molecular Diagnostics

Mycotoxins are toxic metabolites produced by different moulds or fungi, which can form on plants either during growth or whilst in storage. Various moulds of the genera Aspergillus and Penicillium such as Penicillium verrucosum, are responsible for the production of the mycotoxin, ochratoxin A (OTA)  a known carcinogen, teratogen and nephrotoxin.

 

February 01, 2013 More +
Ready to make an enquiry Call us on: + 961 1 39 66 77
Or email us